Equity Overview
Price & Market Data
Price: $1.14
Daily Change: -$0.025 / 2.20%
Range: $1.09 - $1.19
Market Cap: $60,818,224
Volume: 818,143
Performance Metrics
1 Week: 39.52%
1 Month: -39.37%
3 Months: -44.40%
6 Months: -22.46%
1 Year: -30.07%
YTD: -51.70%
Company Details
Employees: 33
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.